Persistent HIV RNA shedding in semen despite effective antiretroviral therapy

Department of Medicine, Dalla Lana School of Public Health, Toronto, Ontario, Canada.
AIDS (London, England) (Impact Factor: 6.56). 09/2009; 23(15):2050-4. DOI: 10.1097/QAD.0b013e3283303e04
Source: PubMed

ABSTRACT Effective antiretroviral therapy (ART) may reduce HIV sexual transmission by lowering genital HIV levels. A prospective study of men starting ART (n = 25) demonstrated rapid, substantial reductions in semen HIV RNA. However, despite an undetectable blood viral load, isolated semen HIV shedding was detected at more than one visit in 12 of 25 (48%) participants, with semen HIV RNA levels exceeding 5000 copies/ml in four of 25 (16%). Isolates were drug-sensitive, and this phenomenon was not associated with semen drug levels or regimen.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus (HIV) may be transmitted through either cell-free virions or leukocytes harboring intracellular HIV in bodily fluids. In recent years, the early initiation of combination antiretroviral therapy leading to virological suppression has resulted in decreased HIV transmission to uninfected partners. Additionally, the efficacy of primary chemoprophylaxis with oral or topical antiretroviral regimens containing tenofovir (with or without emtricitabine) has been demonstrated. However, the efficacy of these approaches may be compromised by suboptimal adherence, decreased drug concentrations in mucosal compartments in women, and genital inflammation. Furthermore, in vitro studies on the effects of tenofovir on cell-associated HIV transmission have produced conflicting results. Preclinical studies suggest that combination preventive approaches may be most effective in stopping the transmission of HIV after mucosal exposure. Since the development of antibodies were found to correlate with protection in the only effective HIV vaccine trial, the administration of preformed mucosal and systemic antibodies may inform the development of safe and effective antibody-based oral, topical, and/or systemic preexposure prophylaxis agents and provide guidance in the development of HIV vaccines that effectively block cell-associated HIV transmission. © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail:
    The Journal of Infectious Diseases 12/2014; 210(suppl 3):S674-S680. DOI:10.1093/infdis/jiu398 · 5.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Individual health benefits of antiretroviral therapy (ART) are becoming clearer. In resource-rich countries, side effects of current ART regimens are minimal. US guidelines recommend ART regardless of CD4 count or viral load. Maintaining an undetectable viral load with ART comes close to eliminating the risk of HIV transmission, leading the US guidelines to recommend universal ART to reduce HIV transmission. Achieving population-level control through treatment as prevention (TasP) may be feasible, but requires considerable investment of resources devoted to HIV testing, linkage to care, ART accessibility, and retention in care. Ongoing studies of TasP will provide insight into achieving meaningful ART coverage.
    Infectious Disease Clinics of North America 10/2014; 28(4). DOI:10.1016/j.idc.2014.08.003 · 2.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although semen is the principal vector of human immunodeficiency virus (HIV) dissemination worldwide, the origin of the infected leukocytes and free viral particles in this body fluid remain elusive. Here we review the accumulated evidence of the genital origin of HIV in semen from therapy naive individuals and men receiving suppressive highly active antiretroviral therapy (HAART), summarize the data on the detection and localization of HIV/SIV within the male genital tract, discuss the potential involvement of each genital tissue as a source of infected cells and virions in semen in the absence and presence of HAART, and suggest further studies. Deci-phering the exact sources of HIV in semen will be crucial to improving HIV transmission prevention strategies. Semen is composed of cells and secretions arising from the male genital tract (MGT), which encompasses sev-eral exocrine organs and ducts (Figure 1). Although semen represents the major vehicle of human immuno-deficiency virus (HIV) transmission, the origins of infected leukocytes and virions in this body fluid re-main unclear. HIV contaminates semen during the acute, chronic, and AIDS stages of infection. Impor-tantly, HIV shedding persists in the semen of a subset of individuals receiving suppressive highly active antire-troviral therapy (HAART), indicating that the male genital tract may constitute a viral reservoir. Here we re-view evidence of a local origin of HIV in semen based on (1) the phylogenetic comparisons of HIV and simian immunodeficiency virus (SIV) strains in semen and blood; (2) the findings of HIV persistence in the semen of men receiving suppressive HAART; and (3) the detection/localization of HIV/SIV within MGT tis-sues. The potential contribution of each MGT tissue to semen contamination by HIV is finally discussed.